Novartis Ag (NVS) Amortization - Intangibles (2009 - 2015)
Novartis Ag (NVS) posted Amortization - Intangibles of -$3.8 billion for Q4 2015, down 35.32% sequentially from -$2.8 billion in Q4 2014, and down 35.32% YoY from -$5.8 billion in Q4 2014.
Novartis Ag (NVS) Amortization - Intangibles (2009 - 2015) Analysis & Trends
Novartis Ag has reported Amortization - Intangibles for 6 years, with the latest figure at -$3.8 billion in Q4 2015.
- Quarterly Amortization - Intangibles fell 35.32% year-over-year to -$3.8 billion in Q4 2015, while the trailing twelve-month figure through Dec 2015 was -$9.2 billion (down 39.65% YoY) and the FY2010 annual result came in at -$1.1 billion, down 10.73% from the prior year.
- Amortization - Intangibles declined to -$3.8 billion in Q4 2015 per NVS's latest filing, from -$2.8 billion in the prior quarter.
- Over five years, Amortization - Intangibles peaked at $147.0 in Q1 2011 and troughed at -$3.8 billion in Q4 2015.
- A 4-year average of -$2.3 billion and a median of -$2.7 billion in 2013 frame the typical range for Amortization - Intangibles.
- The sharpest annual moves came in 2014 and 2015: Amortization - Intangibles fell 2.85% in 2014, then slumped 35.32% in 2015.
- Over 4 years, Amortization - Intangibles stood at $147.0 in 2011, then slumped by 1835374249.66% to -$2.7 billion in 2013, then decreased by 2.85% to -$2.8 billion in 2014, then slumped by 35.32% to -$3.8 billion in 2015.
- According to Business Quant data, Amortization - Intangibles over the past three periods registered -$3.8 billion, -$2.8 billion, and -$2.7 billion for Q4 2015, Q4 2014, and Q4 2013 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | -3.76 Bn |
| Dec 31, 2014 | -2.78 Bn |
| Dec 31, 2013 | -2.70 Bn |
| Mar 31, 2011 | 147.00 |
| Dec 31, 2010 | -1.14 Bn |
| Mar 31, 2010 | 164.00 |
| Dec 31, 2009 | -1.03 Bn |